ATRO Medical, a Netherlands-based clinical-stage orthopedic medical device company, has secured €3 million in a new financing round to advance development of its Artimis Meniscus Prosthesis, an artificial meniscus implant designed for patients suffering from post-meniscectomy pain syndrome.
The financing consists primarily of equity investments, complemented by non-dilutive funding, and includes participation from MedTech investors across the Netherlands, Switzerland, and the United Arab Emirates. Investors include 819 Capital, Thuja Capital, Bolwork International Investment, DSM-Firmenich Ventures, and Samaplast.
The funding comes as the company reaches a key milestone in the clinical evaluation of its latest Artimis Meniscus Prosthesis design. Ongoing studies are evaluating the artificial meniscus system in patients with persistent knee pain after meniscus removal. ATRO Medical has also strengthened its intellectual property position and gained international exposure through its selection for the PlugAndPlay Health incubator in the United States, positioning the company for its next stage of growth.
The newly raised capital will be used to expand clinical evidence generation, prepare for pivotal clinical trials in both the United States and Europe, and further optimize manufacturing, regulatory readiness, and clinical operations.
As part of the financing, ATRO Medical announced a strategic leadership transition to support its next phase. Maarten van der Zanden has been appointed chief executive officer, transitioning from his previous role as chief implementation officer. Anita Brinks will continue as chief operating officer, overseeing operations and quality systems as the company prepares for pivotal clinical programs. Founder Tony van Tienen will focus on clinical strategy, surgeon engagement, and scientific development as chief medical officer, alongside his practice as a knee surgeon at the Viasana Clinic.
The company also plans to extend the current financing round through a share funding campaign on the Eyevestor platform following strong interest from private investors and patients. The campaign, launching in March, will enable individuals to participate in ATRO Medical’s next phase of clinical development and international expansion.
ATRO Medical is focused on addressing a significant treatment gap affecting hundreds of thousands of patients worldwide who experience persistent knee pain after meniscus removal, often combined with progressive osteoarthritis at a relatively young age. The Artimis Meniscus Prosthesis is designed to restore joint biomechanics, relieve pain, and preserve future treatment options. With the new financing, the company aims to accelerate clinical development and move closer to regulatory approvals in the United States and Europe.
KEY QUOTES
“This investment reflects strong international confidence in ATRO Medical’s technology, team and strategy. The recent clinical outcomes confirm that we have cracked the code for patients with post-meniscectomy pain. With this experienced leadership team and a clear path toward pivotal studies in the US and Europe, ATRO Medical is entering a defining phase in its development.”
Michiel Schwartz, Chairman of the Board, ATRO Medical
